RUZURGI® IS NOW AVAILABLE AND COVERED BY THE VAST MAJORITY OF PUBLIC HEALTH AND PRIVATE INSURANCE PLANS

BLAINVILLE, Quebec (Canada) – July 11th, 2023 – Médunik Canada, member of Duchesnay Pharmaceutical Group, is pleased to announce that Ruzurgi® (amifampridine) is now covered by the vast majority of provincial and federal public health programs and many private insurance plans through special authorization. More than 90% of Canadians suffering from Lambert-Eaton Myasthenic Syndrome (LEMS) will benefit from this extensive coverage.

Read more

Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi® (amifampridine) following a favourable Canadian Federal Court of Appeal ruling

BLAINVILLE (Quebec), January  17, 2023  -- Medunik Canada Inc. (“Medunik”), a company dedicated to improving the health and quality of life of Canadians with rare diseases by bringing orphan drugs to Canada, is pleased to announce that on January 9, 2023, the Federal Court of Appeal of Canada set aside an earlier decision of its Trial Division which had removed a Notice of Compliance on Medunik’s Ruzurgi® (amifampridine) for Lambert-Eaton Myasthenic Syndrome ("LEMS") patients and sent the matter back to Health Canada.

Read more